Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAMSEY JOUDEH

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1174819353
CMS profile
1222432
Location
BROOKLYN, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$149.84

16 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $149.84 16

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
Salix Pharmaceuticals, a division of Bausch Health US, LLC $149.84 16

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAMSEY JOUDEH

NPI 1174819353 · CMS profile ID 1222432

Allopathic & Osteopathic Physicians / Internal Medicine

BROOKLYN, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174819353?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAMSEY JOUDEH, NPI 1174819353, CMS profile ID 1222432. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174819353?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). RAMSEY JOUDEH, NPI 1174819353, CMS profile ID 1222432. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174819353?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
RAMSEY JOUDEH, NPI 1174819353, CMS profile ID 1222432, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1174819353?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

16 matching records · $149.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 16 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–16 of 16.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.9112/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959406035 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $4.3412/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960050541 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $9.2110/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959578811 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $6.7310/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959620735 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $0.8310/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959768395 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $10.1210/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959822795 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $4.4510/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959906849 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.2308/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959806901 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.8007/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959754139 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $19.5007/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960005191 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.1806/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959984287 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $14.1805/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960051593 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $6.3002/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959708447 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $9.1202/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959896435 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $5.4701/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959415847 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $8.4701/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 959545499 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $276.49 19
PY2020 $18.21 1
PY2021 $206.03 6
PY2022 $149.84 16
PY2023 $294.93 16
PY2024 $619.11 29
PY2025 $368.57 20

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $387,424.01 98
PY2024 Principal investigator $479,966.08 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

98 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $2,000.00 12/23/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003799
Principal investigator 1 ModernaTX, Inc. $3,166.35 11/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956497
Principal investigator 1 ModernaTX, Inc. $543.40 11/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956505
Principal investigator 1 ModernaTX, Inc. $966.15 11/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956543
Principal investigator 1 GlaxoSmithKline, LLC. $87.75 11/04/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180559
Principal investigator 1 GlaxoSmithKline, LLC. $175.50 11/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180066
Principal investigator 1 ModernaTX, Inc. $966.15 10/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956471
Principal investigator 1 ModernaTX, Inc. $438.90 10/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956487
Principal investigator 1 ModernaTX, Inc. $522.50 09/29/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956545
Principal investigator 1 AstraZeneca Pharmaceuticals LP $60,313.24 09/24/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure No dispute reported 06/30/2026 1185547671
Principal investigator 1 GlaxoSmithKline, LLC. $87.75 09/12/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192141310
Principal investigator 1 GlaxoSmithKline, LLC. $175.50 09/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192141952
Principal investigator 1 GlaxoSmithKline, LLC. $87.75 09/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192141996
Principal investigator 1 GlaxoSmithKline, LLC. $270.00 09/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180081
Principal investigator 1 GlaxoSmithKline, LLC. $182.25 09/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180563
Principal investigator 1 GlaxoSmithKline, LLC. $558.50 09/11/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180587
Principal investigator 1 GlaxoSmithKline, LLC. $9,071.37 09/09/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192141978
Principal investigator 1 ModernaTX, Inc. $2,110.90 08/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956465
Principal investigator 1 ModernaTX, Inc. $668.80 08/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956479
Principal investigator 1 ModernaTX, Inc. $322.05 08/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956531
Principal investigator 1 ModernaTX, Inc. $7,113.60 08/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003819
Principal investigator 1 GlaxoSmithKline, LLC. $4,243.93 08/18/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192141959
Principal investigator 1 GlaxoSmithKline, LLC. $94.50 08/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192141316
Principal investigator 1 GlaxoSmithKline, LLC. $175.50 08/06/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180583
Principal investigator 1 ModernaTX, Inc. $125.40 07/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956475
Principal investigator 1 ModernaTX, Inc. $1,055.45 07/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956539
Principal investigator 1 GlaxoSmithKline, LLC. $4,243.93 07/14/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192141991
Principal investigator 1 ModernaTX, Inc. $1,055.45 06/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956473
Principal investigator 1 ModernaTX, Inc. $459.80 06/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956501
Principal investigator 1 GlaxoSmithKline, LLC. $18,757.54 06/20/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192141322
Principal investigator 1 ModernaTX, Inc. $689.70 06/18/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956509
Principal investigator 1 ModernaTX, Inc. $3,166.35 06/18/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956537
Principal investigator 1 ModernaTX, Inc. $322.05 06/18/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956551
Principal investigator 1 ModernaTX, Inc. $18,969.60 06/18/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003815
Principal investigator 1 PFIZER INC. $500.00 06/17/2025 Non-covered Recipient Entity
Dynamed New Jersey LLC dba DM Clinical Research New Jersey
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702702
Principal investigator 1 PFIZER INC. $750.00 06/17/2025 Non-covered Recipient Entity
Dynamed New Jersey LLC dba DM Clinical Research New Jersey
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702704
Principal investigator 1 GlaxoSmithKline, LLC. $875.00 06/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192142004
Principal investigator 1 GlaxoSmithKline, LLC. $875.00 06/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180090
Principal investigator 1 GlaxoSmithKline, LLC. $875.00 06/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180567
Principal investigator 1 GlaxoSmithKline, LLC. $875.00 06/05/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180590
Principal investigator 1 ModernaTX, Inc. $1,055.45 05/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956481
Principal investigator 1 ModernaTX, Inc. $2,898.45 05/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956489
Principal investigator 1 ModernaTX, Inc. $752.40 05/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956549
Principal investigator 1 ModernaTX, Inc. $71,136.00 05/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003801
Principal investigator 1 ModernaTX, Inc. $1,062.00 05/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003809
Principal investigator 1 GlaxoSmithKline, LLC. $8,219.48 05/27/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180572
Principal investigator 1 GlaxoSmithKline, LLC. $87.75 04/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192141947
Principal investigator 1 GlaxoSmithKline, LLC. $87.75 04/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192141972
Principal investigator 1 GlaxoSmithKline, LLC. $4,109.74 04/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180074
Principal investigator 1 GlaxoSmithKline, LLC. $87.75 04/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180077
Principal investigator 1 GlaxoSmithKline, LLC. $4,109.74 04/28/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180578
Principal investigator 1 ModernaTX, Inc. $148.50 04/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956499
Principal investigator 1 ModernaTX, Inc. $333.30 04/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956503
Principal investigator 1 ModernaTX, Inc. $883.00 04/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956507
Principal investigator 1 ModernaTX, Inc. $457.65 04/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956511
Principal investigator 1 ModernaTX, Inc. $627.00 04/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956515
Principal investigator 1 ModernaTX, Inc. $61.60 04/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956525
Principal investigator 1 ModernaTX, Inc. $3,220.50 04/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956547
Principal investigator 1 ModernaTX, Inc. $354.00 04/28/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003803
Principal investigator 1 ModernaTX, Inc. $1,412.80 04/11/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956463
Principal investigator 1 ModernaTX, Inc. $222.20 04/11/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956485
Principal investigator 1 ModernaTX, Inc. $118.65 04/11/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956493
Principal investigator 1 ModernaTX, Inc. $107.80 04/11/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956521
Principal investigator 1 ModernaTX, Inc. $33.00 04/11/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956529
Principal investigator 1 ModernaTX, Inc. $4,800.00 04/11/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003821
Principal investigator 1 GlaxoSmithKline, LLC. $7,500.00 04/03/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192141986
Principal investigator 1 AstraZeneca Pharmaceuticals LP $26,700.00 04/02/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH LP
a phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like particle VLP vaccine in adults 60 years of age and older No dispute reported 06/30/2026 1185547673
Principal investigator 1 GlaxoSmithKline, LLC. $87.75 04/01/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180069
Principal investigator 1 GlaxoSmithKline, LLC. $87.75 03/31/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192141965
Principal investigator 1 GlaxoSmithKline, LLC. $351.00 03/31/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180062
Principal investigator 1 ModernaTX, Inc. $606.10 03/24/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956467
Principal investigator 1 ModernaTX, Inc. $1,055.45 03/24/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956495
Principal investigator 1 ModernaTX, Inc. $1,610.25 03/24/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956517
Principal investigator 1 ModernaTX, Inc. $708.00 03/24/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003823
Principal investigator 1 GlaxoSmithKline, LLC. $4,151.25 03/21/2025 Non-covered Recipient Entity
DYNAMED CLINICAL RESEARCH- JERSEY CITY
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192180085
Principal investigator 1 GlaxoSmithKline, LLC. $4,109.74 03/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH OF ROCK HILL
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192141304
Principal investigator 1 ModernaTX, Inc. $1,288.20 02/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956519
Principal investigator 1 ModernaTX, Inc. $3,355.40 02/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956527
Principal investigator 1 ModernaTX, Inc. $250.80 02/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956533
Principal investigator 1 ModernaTX, Inc. $877.80 02/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956535
Principal investigator 1 ModernaTX, Inc. $5,277.25 02/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956541
Principal investigator 1 ModernaTX, Inc. $1,416.00 02/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003805
Principal investigator 1 ModernaTX, Inc. $4,742.40 02/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003807
Principal investigator 1 ModernaTX, Inc. $1,150.00 02/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003813
Principal investigator 1 ModernaTX, Inc. $3,000.00 02/24/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003817
Principal investigator 1 ModernaTX, Inc. $15,000.00 02/19/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003797
Principal investigator 1 ModernaTX, Inc. $16,777.00 02/17/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956477
Principal investigator 1 ModernaTX, Inc. $6,710.80 01/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956469
Principal investigator 1 ModernaTX, Inc. $2,254.35 01/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956491
Principal investigator 1 ModernaTX, Inc. $668.80 01/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956513
Principal investigator 1 ModernaTX, Inc. $459.80 01/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956523
Principal investigator 1 ModernaTX, Inc. $304.00 01/27/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253003811
Principal investigator 1 ModernaTX, Inc. $15,000.00 01/24/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956461
Principal investigator 1 ModernaTX, Inc. $3,000.00 01/23/2025 Non-covered Recipient Entity
DYNAMED NEW JERSEY LLC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252956483
Principal investigator 1 PFIZER INC. $1,600.00 01/18/2025 Non-covered Recipient Entity
Dynamed New Jersey LLC dba DM Clinical Research New Jersey
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702504
Principal investigator 1 PFIZER INC. $500.00 01/18/2025 Non-covered Recipient Entity
Dynamed New Jersey LLC dba DM Clinical Research New Jersey
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702642
Principal investigator 1 PFIZER INC. $1,500.00 01/18/2025 Non-covered Recipient Entity
Dynamed New Jersey LLC dba DM Clinical Research New Jersey
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228702700
Principal investigator 1 PFIZER INC. $1,000.00 01/18/2025 Non-covered Recipient Entity
Dynamed New Jersey LLC dba DM Clinical Research New Jersey
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED EFFICACY AND TOLERABILITY TRIAL OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS UNSUITABLE FOR TRIPTAN USE No dispute reported 06/30/2026 1228711324